Offering hope with a new approach designed to address significant unmet needs

At Avalo, our mission is to transform lives with novel therapeutics targeting immune-mediated inflammatory diseases that realize the promise of best-in-class and best-in-disease medicines. We are deeply inspired by the experiences and stories of people living with a variety of inflammatory conditions. Our ongoing conversations with you give us key insights that we apply to our programs and that help fuel our urgent commitment to developing innovative treatments that have a meaningful impact on the lives of the people with these serious diseases.

If you or someone you love is living with hidradenitis suppurativa (HS) and would like to engage in conversation, we invite you to contact us at advocacy@www.avalotx.com.^*

Learn more about our lead investigational drug, AVTX-009

*By providing your information, you agree to allow Avalo Therapeutics to collect the name and email address provided and to be contacted by Avalo Therapeutics and its partners using this information.

Clinical trials

Now enrolling

A study to evaluate the efficacy and safety of AVTX-009 in people with moderate to severe hidradenitis suppurativa (HS)

Visit the LOTUS website to learn more

Who can participate: Adults with HS
Length of study: Up to 24 weeks (about 6 months)
Number of visits: 12 total (about 1 visit every 2 weeks)
Number of participants: About 222 patients
Locations: Global study sites

Resources

For more information about HS and access to resources for people with HS, visit these sites:

Access to investigational therapies

Avalo Therapeutics’ goal is to provide potentially impactful therapies to people who may benefit from them, while minimizing potential risk. We believe that clinical trials are the most effective way for people to access investigational products, as clinical trials can generate data that may lead to the approval of new medicines and wider availability to people living with disease.

Overview of our clinical trials